FDA Approves Secukinumab for Adolescents with Severe Chronic Skin Disease

In an important development for adolescent dermatology, the U.S. Food and Drug Administration (FDA) has approved secukinumab (Cosentyx) for adolescents aged 12 years and older with moderate to severe hidradenitis suppurativa (HS).

This decision marks a major step forward in treatment options, as secukinumab becomes the first IL-17A inhibitor approved specifically for adolescents suffering from this chronic inflammatory skin condition.

For young patients who have struggled with limited treatment choices, this approval offers new hope for earlier and more effective disease management.

Understanding Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory skin disease that causes painful, boil-like lumps beneath the skin. These lesions often appear in areas where skin rubs together, such as the armpits, groin, and under the breasts.

Over time, the lesions may rupture, leading to open wounds, drainage, and permanent scarring. In severe cases, HS can significantly impact daily activities and overall quality of life.

Many patients first experience symptoms during puberty or their teenage years. Unfortunately, diagnosis is frequently delayed sometimes by up to 10 years which allows the disease to progress before proper treatment begins.

Beyond the physical symptoms, HS can also affect confidence, emotional well-being, and social relationships, especially during adolescence when self-image and social development are particularly important.

Filling a Major Treatment Gap

Before this approval, treatment options for adolescents with moderate to severe HS were very limited. Expanding the use of secukinumab to younger patients helps address a long-standing gap in dermatological care.

Secukinumab works by targeting and blocking IL-17A, a key inflammatory protein involved in immune-mediated diseases such as HS, psoriasis, and certain types of arthritis. By reducing this inflammatory response, the medication can help control symptoms and prevent disease progression.

The drug is already approved for several immune-related conditions, including:

• Plaque psoriasis
• Juvenile psoriatic arthritis
• Ankylosing spondylitis

The new approval now extends its benefits to adolescents living with hidradenitis suppurativa.

Clinical Trial Results Supporting Approval

The FDA’s decision was supported by strong clinical research, including the SUNSHINE and SUNRISE Phase 3 trials involving more than 1,000 adult patients with HS.

Results from these studies showed that patients receiving secukinumab experienced significantly better clinical outcomes compared with those receiving a placebo. Improvements were observed as early as 16 weeks, based on the Hidradenitis Suppurativa Clinical Response (HiSCR) measurement.

Importantly, the treatment demonstrated consistent effectiveness regardless of whether patients had previously used biologic therapies or were receiving biologic treatment for the first time.

For adolescents, dosing is adjusted based on body weight, particularly for patients weighing 30 kilograms or more, ensuring safe and appropriate drug exposure comparable to successful adult treatment results.

Safety Considerations

As with other biologic therapies that affect the immune system, secukinumab requires careful medical supervision.

Because the medication modifies immune activity, it may increase the risk of serious infections, including:

• Tuberculosis
• Bacterial infections
• Viral infections
• Fungal infections

Patients are typically screened for tuberculosis before starting treatment, and healthcare providers monitor them for signs of infection or other complications during therapy.

Common side effects reported in clinical trials include:

• Cold-like symptoms
• Diarrhea
• Upper respiratory infections

Additionally, patients may be monitored for new or worsening inflammatory bowel disease, as flare-ups have been associated with this class of medications.

A Step Forward for Younger Patients

Since its launch in 2015, secukinumab has been used to treat more than 1.8 million patients worldwide across multiple immune-mediated conditions. The new FDA approval now extends its potential benefits to adolescents facing the challenges of hidradenitis suppurativa.

For the estimated 1 in 100 people globally affected by HS, earlier access to targeted treatments could help reduce long-term complications, improve symptom control, and enhance overall quality of life.

As research in dermatology continues to advance, approvals like this represent meaningful progress in ensuring that younger patients receive timely, effective care for chronic skin conditions.

At MediServ Pharmacy, we understand that chronic skin conditions like hidradenitis suppurativa often require personalized treatment approaches. As a trusted compounding pharmacy in NYC providing customized medications for dermatological conditions, we work closely with healthcare providers to prepare tailored prescriptions that meet each patient’s specific needs. Our team specializes in creating customized topical formulations and unique dosage options that support more effective care. If you’re looking for a reliable compounding pharmacy in NYC for personalized dermatology medications, we are here to help. Visit our website to learn more about our compounding services and how we support better patient outcomes.